HUP0002913A2 - Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára - Google Patents

Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára

Info

Publication number
HUP0002913A2
HUP0002913A2 HU0002913A HUP0002913A HUP0002913A2 HU P0002913 A2 HUP0002913 A2 HU P0002913A2 HU 0002913 A HU0002913 A HU 0002913A HU P0002913 A HUP0002913 A HU P0002913A HU P0002913 A2 HUP0002913 A2 HU P0002913A2
Authority
HU
Hungary
Prior art keywords
expression system
vivo
subject
cell
interferon
Prior art date
Application number
HU0002913A
Other languages
English (en)
Inventor
James G. Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP0002913A2 publication Critical patent/HUP0002913A2/hu
Publication of HUP0002913A3 publication Critical patent/HUP0002913A3/hu
Publication of HU224422B1 publication Critical patent/HU224422B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya sejtexpressziós rendszer szekretált fehérje(előnyösen interferon) in vivo expresszálására emlősrecipiens(előnyösen ember) sejtjében például tumor kezelésére. Az expressziósrendszer rekombináns adenovírus-vektort tartalmaz, melyet hordozókéntalkalmaznak géntermék in situ biztosítására. Az expressziós rendszertalkalmazó ex vivo génterápiás eljárásban emlősrecipiensből származósejtet genetikailag módosítanak szekretált fehérjét, előnyöseninterferont kódoló DNS-sel, majd beadják az emlősrecipiensnek akezelésre szoruló helyre; valamint in vivo génterápiás eljárásban azexpressziós vektort közvetlenül a kezelendő alany sejtjébe juttatják.A találmány tárgya expressziós rendszert tartalmazógyógyszerkészítmény is. A vizsgálatok szerint IFN-b-gén ex vivo célbajuttatása tumorba a sejtek nagyon kis százalékában (legalább 0,3%)elegendő volt a tumorképződés blokkolására, és egyetlen dózisból állóközvetlen intratumorális IFN-b-génbevitel kialakult tumorokvisszafejlődéséhez vezetett. Ó
HU0002913A 1997-08-29 1998-08-25 Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára HU224422B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (3)

Publication Number Publication Date
HUP0002913A2 true HUP0002913A2 (hu) 2000-12-28
HUP0002913A3 HUP0002913A3 (en) 2003-08-28
HU224422B1 HU224422B1 (hu) 2005-08-29

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002913A HU224422B1 (hu) 1997-08-29 1998-08-25 Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára

Country Status (25)

Country Link
EP (1) EP1007717B8 (hu)
JP (3) JP4124565B2 (hu)
KR (1) KR100699285B1 (hu)
CN (1) CN100342019C (hu)
AT (1) ATE316145T1 (hu)
AU (1) AU740428B2 (hu)
BR (1) BR9812138A (hu)
CA (1) CA2300480C (hu)
CY (1) CY1105029T1 (hu)
CZ (2) CZ297314B6 (hu)
DE (1) DE69833264T2 (hu)
DK (1) DK1007717T3 (hu)
EA (1) EA003256B1 (hu)
EE (1) EE04873B1 (hu)
ES (1) ES2257817T3 (hu)
HK (1) HK1029599A1 (hu)
HU (1) HU224422B1 (hu)
IL (2) IL134593A0 (hu)
IS (1) IS2318B (hu)
NO (1) NO20000990L (hu)
NZ (1) NZ503401A (hu)
PT (1) PT1007717E (hu)
SK (1) SK286821B6 (hu)
TR (1) TR200000532T2 (hu)
WO (1) WO1999010516A2 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502585A (ja) 2001-01-22 2005-01-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 治療的核酸の送達を増強するための方法
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
WO2020247321A1 (en) * 2019-06-01 2020-12-10 Sivec Biotechnologies, Llc A bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
AU711269B2 (en) * 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
EA003256B1 (ru) 2003-02-27
IL134593A0 (en) 2001-04-30
EP1007717B1 (en) 2006-01-18
CN100342019C (zh) 2007-10-10
ES2257817T3 (es) 2006-08-01
HU224422B1 (hu) 2005-08-29
WO1999010516A3 (en) 1999-05-06
JP2001514010A (ja) 2001-09-11
JP4219335B2 (ja) 2009-02-04
WO1999010516A2 (en) 1999-03-04
CZ297314B6 (cs) 2006-11-15
NZ503401A (en) 2003-01-31
AU740428B2 (en) 2001-11-01
JP4124565B2 (ja) 2008-07-23
EA200000270A1 (ru) 2000-10-30
IS5374A (is) 2000-02-11
NO20000990D0 (no) 2000-02-28
IL134593A (en) 2007-06-17
IS2318B (is) 2007-11-15
KR100699285B1 (ko) 2007-03-26
CY1105029T1 (el) 2010-03-03
NO20000990L (no) 2000-05-02
JP2004155786A (ja) 2004-06-03
HK1029599A1 (en) 2001-04-06
BR9812138A (pt) 2000-07-18
CN1271391A (zh) 2000-10-25
EP1007717A2 (en) 2000-06-14
SK286821B6 (sk) 2009-06-05
AU9205198A (en) 1999-03-16
SK2482000A3 (en) 2000-08-14
EP1007717B8 (en) 2006-05-03
CA2300480C (en) 2010-01-05
EE04873B1 (et) 2007-08-15
DE69833264T2 (de) 2006-09-28
EE200000102A (et) 2000-12-15
DE69833264D1 (de) 2006-04-06
PT1007717E (pt) 2006-06-30
CZ2000733A3 (cs) 2000-06-14
DK1007717T3 (da) 2006-05-29
CZ299095B6 (cs) 2008-04-23
TR200000532T2 (tr) 2000-11-21
CA2300480A1 (en) 1999-03-04
HUP0002913A3 (en) 2003-08-28
ATE316145T1 (de) 2006-02-15
KR20010023511A (ko) 2001-03-26
JP2005225888A (ja) 2005-08-25
JP3953458B2 (ja) 2007-08-08

Similar Documents

Publication Publication Date Title
KR100392984B1 (ko) 유전자치료를위한단구-마크로파아지세포계로부터의재조합세포
Cirone et al. A novel approach to tumor suppression with microencapsulated recombinant cells
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
ATE320186T1 (de) Nukleinsäure zur verwendung in gentherapie, welche therapie intestinale zell-expression der genen involviert
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
CA2567177A1 (en) Genetically engineered cells for therapeutic applications
WO2018137643A1 (zh) 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
O’Malley Jr et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer
Wan et al. Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy
Aquino et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
Lu et al. Cationic liposome-mediated GDNF gene transfer after spinal cord injury
JP2003526685A (ja) 腫瘍治療用の全身性遺伝子送達運搬体
Shao et al. KERS‐Inspired Nanostructured Mineral Coatings Boost IFN‐γ mRNA Therapeutic Index for Antitumor Immunotherapy
Lamsam et al. Gene therapy in sports medicine
PT684842E (pt) Composicao para o tratamento de tumores e para a imunizacao de organismos contra tumores
AU717974B2 (en) Transduced human hematopoietic stem cells
US20020028783A1 (en) Method of stimulating prosaposin receptor activity
DK1032429T3 (da) Fremgangsmåde til DNA-afgivelse in vivo ved anvendelse af et nålefrit apparatur
JP2011084569A (ja) プロサポシン受容体活性を刺激する方法
US20100260734A1 (en) Method of stimulating prosaposin receptor activity
JP2002524468A (ja) プロサポシン受容体活性を刺激する方法
JP2022050254A (ja) 滑膜細胞増殖抑制剤、関節腔注入剤、及び食品組成物
Marumo et al. Application of the interferon minipellet to human renal cell carcinoma in nude mice
Mobley The promise of gene therapy in head and neck cancer

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050720

MM4A Lapse of definitive patent protection due to non-payment of fees